Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting

Abstract Introduction Real‐world data are critical to demonstrate the consistency of evidence and external generalizability of randomized controlled trials (RCTs). This study examined characteristics and outcomes of metastatic triple‐negative breast cancer (mTNBC) patients treated with eribulin mesy...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Sarah S. Mougalian, Ronda Copher, Jonathan K. Kish, Lindsay McAllister, Zhixiao Wang, Mary Broscious, David Garofalo, Janna Radtchenko, Bruce A. Feinberg
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2018-09-01
Edice:	Cancer Medicine
Témata:	eribulin metastatic breast cancer real‐world survival triple negative
On-line přístup:	https://doi.org/10.1002/cam4.1705
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!